News

Pulmonary hypertension is a condition caused by increased pressure in the pulmonary arteries. In advanced cases, its symptoms (shortness of breath, tiredness, chest pain) worsen and may limit all physical activity. Now, researchers from University of California, Los Angeles have developed a successful treatment to rescue advanced forms of…

Biopharm company, Insmed Incorporated, has announced that they will present their novel inhalation technologies for the treatment of orphan pulmonary diseases such as pulmonary arterial hypertension at the European Respiratory Society’s (ERS) International Congress 2014. Held between September 6th and 10th at the Internationales Congress Center München, in…

Idiopathic pulmonary fibrosis (IPF) is an uncommon, yet deadly respiratory disease, characterized by a progressive decline in pulmonary function caused by lung scarring — the cause of which remains unknown today. Patients diagnosed with IPF along with their significant others recently received the good news that they are finally…

The U.S. District Court for the District of New Jersey has ruled in United Therapeutics Corporation‘s favor in the company’s case against Sandoz, regarding United Therapeutics’ Remodulin product. First approved in the United States in May 2002, Remodulin is a prostacyclin vasodilator used for the treatment of pulmonary arterial…

The U.S. Food and Drug Administration has granted APD811, an investigational drug candidate internally developed by Arena Pharmaceuticals, orphan drug status. APD811 is an oral agonist of the prostacyclin (IP) receptor, which is designed for the treatment of vasospastic diseases, such as pulmonary arterial hypertension (PAH). “The FDA Office of…

Omentin, an adipocyte-derived cytokine, is a potential novel candidate to treat obesity-related cardiovascular disease. Dr. Kyosuke Kazama and colleagues from the School of Veterinary Medicine, Kitasato University, Japan, have shown for the first time that long term treatment for 14 days with omentin inhibits vascular structural remodeling and abnormal contractile…

The first results of AMBITION, a large pulmonary arterial hypertension clinical trial, will be presented this month at the European Respiratory Society (ERS) International Congress 2014, as part of the highlights of the meeting. AMBITION is a randomized, double blind, multi center Phase 4 clinical trial testing the efficacy…

The American College of Chest Physicians’ (CHEST) series of guidelines for the management and treatment of pulmonary arterial hypertension (PAH) in adults, which was published this summer in the CHEST journal, has been officially endorsed by the country’s leading pulmonary hypertension association, the Pulmonary Hypertension Association…

Sorrento Therapeutics, Inc., a late-stage clinical oncology company, has announced that it will advance with its immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of idiopathic pulmonary fibrosis (IPF). IPF is a chronic and fatal disease that occurs in individuals between 50 and 70 years of…

UCLA researchers have shown that oxidized lipids may contribute to pulmonary hypertension (PH), a progressive and incurable disease that is responsible for narrowing the small blood vessels in the lungs. In a study entitled “Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3p”…

The Pulmonary Hypertension Association (PHA) is hosting a webinar about the health value of exercise for pulmonary hypertension patients. The event, called “Exercising Mindfully with PH,” will take place Thursday, August 28 at the PHA head office, and will be presented by Rana Lee Adawi…

A group of researchers from the University of Pécs, Hungary, have attempted to understand the mechanism by which pulmonary vascular remodeling initiates right ventricular failure and hypoxia, one of the leading causes behind the mortality rates associated with Pulmonary Hypertension (PH). Sildenafil, known more commonly by its…